Revir Therapeutics is a biotechnology company that develops mRNA-modifying small molecules to treat Huntington's Disease and other neurogenetic disorders.

Revir Therapeutics

ReviR Therapeutics is a research and development company whose mission is to harness advanced technologies, machine learning/AI, and the inherent biology embedded within RNA to develop novel medicines to treat human disease.  Our AI-based platform allows us to expand beyond the protein-based target space to reach a large number of known disease targets previously considered “undruggable”

Strategies
* Invent and build technologies to unlock first-in-class medicines for the treatment of cancer, rare genetic disorders, and infectious diseases
* Decipher disease relevant structural and functional RNA motifs by integrating human genetic data, functional genomics, and AI 
* Integrate Machine Learning tools and advanced the mechanistic understanding of the RNA life cycle at scale in order to deliver transformative therapies for millions of patients 


Shunwei Capital

Sky9 Capital

5Y Capital

Tiantu Capital

CDH Investments

ReviR Therapeutics

We are excited to announce that CMT Research Foundation will sponsor ReviR Therapeutics to develop innovative splice-modulating therapies to treat Charcot Marie Tooth disease type 1A (CMT1A).  https://lnkd.in/gh_edswV
#CMT1A #Splicing #ReviRTherapeutics #CMTRF 
#BiotechNews #TherapeuticDevelopment

A step forward for Huntington's Disease patients today! PTC Therapeutics, Inc. announced 12 month interim data from their ongoing Phase 2 clinical trial of PTC518, a small molecule splicing modulator: evidence of being safe, tolerable, with meaningful clinical benefit: https://lnkd.in/g7NUvxkj

We are pleased to announce a significant step forward for ReviR's splicing modulators for #oncology with Asieris Pharmaceuticals! Shared passion towards cures, driven by innovation #collaboration #vision #drugdiscovery #RNA

https://lnkd.in/g6_UWbDn

We've just wrapped up an invigorating summer internship program at ReviR Therapeutics. Here's a glimpse into the experiences of our remarkable interns.

A Huge Thank You to ReviR’s Scientific Advisory Board!
We want to take a moment to express our sincere gratitude to the incredible members of ReviR’s Scientific Advisory Board.
Your collective feedback, experience, and guidance have been invaluable in shaping our direction as we continue to develop RNA modulating small molecules that are CNS penetrant and orally delivered. Your insights during our recent meeting at our South San Francisco HQ were particularly insightful and will be instrumental in helping us deliver disease modulating therapies to the patients who suffer from neurogenetic diseases, such as Huntington’s Disease. 
[SAB Members Lynne Maquat Ph.D., David Dornan Ph.D.,
Brian Safina Ph.D., Irina Antonijevic MD Ph.D., Elisabetta Morini Ph.D., Julio Medina Ph.D.].


We look forward to continuing to learn from you all and working together to achieve breakthrough therapies for patients who need them most. [ReviR members here. Not pictured Sarah Burnett, Zenia Llamas]

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Jul 29, 2024 3:14 AM	b84a08d2
public peers	general	Jul 29, 2024 12:20 AM	5b4c889a
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Jul 29, 2024 1:27 AM	ee158c08
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Jul 29, 2024 12:20 AM	09233484
translate crunchbase fundingrounds	general
peers	general	Jul 29, 2024 12:20 AM	38a8ebec
news basic	general	Jul 29, 2024 12:20 AM	d4f3deba
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

REVI

COM:REVIRTX

Revir Therapeutics